MVIR:STO
Medivir AB
1,47 SEK
arrow_upward
+0,82%(+0,012) 1D
9 ოქტ, 14:11:37 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for MVIR...
Open
1,47 SEK
High
1,50 SEK
Low
1,45 SEK
Mkt. cap
916,42 მლნ.
Avg. vol.
1,41 მლნ.
Volume
1,23 მლნ.
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 მლნ.
No. of employees
6
Open
1,47 SEK
High
1,50 SEK
Low
1,45 SEK
Mkt. cap
916,42 მლნ.
Avg. vol.
1,41 მლნ.
Volume
1,23 მლნ.
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 მლნ.
No. of employees
6
News stories
From web sources and news partners
Euronews.com
·
11 წუთის წინ
What happened to OpenAI’s $20bn? Revenue scare rattles AI trade
The Globe and Mail
·
17 წუთის წინ
Kaplan Fox Announces a Securities Class Action Filed Against AST SpaceMobile, Inc. (NASDAQ: ASTS) - Lead Plaintiff Deadline is November 13, 2026
Simply Wall Street
·
16 წუთის წინ
Top 3 AI Growth Stocks To Watch In October 2026
Yahoo Finance
·
2 საათის წინ
History says midterms could hand the S&P 500 a year-end rally: Chart of the Day
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB